LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Inicio・Lista de Acciones・Innoviva Inc

Search

Innoviva Inc

Cerrado

SectorSanidad

22.93 2.23

Resumen

Variación precio

24h

Actual

Mínimo

22.5

Máximo

23.32

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.596 49.052
BPA	0.47
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+53.06% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-54M 1.6B
Apertura anterior	20.7
Cierre anterior	22.93

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 344 Clasificación en Healthcare

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 jun 2026, 23:36 UTC

Ganancias

Correction to Oracle Reports Higher 4Q Profit Article

10 jun 2026, 23:19 UTC

Acciones populares

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 jun 2026, 23:09 UTC

Principales Movimientos del Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 jun 2026, 23:04 UTC

Ganancias

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 jun 2026, 20:44 UTC

Principales Movimientos del Mercado

Caterpillar Raises Quarterly Dividend 8%

10 jun 2026, 23:49 UTC

Adquisiciones, fusiones, absorciones

Elliott: Northern Star Should Take No Options Off The Table

10 jun 2026, 23:48 UTC

Adquisiciones, fusiones, absorciones

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 jun 2026, 23:48 UTC

Adquisiciones, fusiones, absorciones

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 jun 2026, 23:47 UTC

Charlas de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 jun 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 jun 2026, 23:46 UTC

Adquisiciones, fusiones, absorciones

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 jun 2026, 23:38 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 jun 2026, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 jun 2026, 23:38 UTC

Charlas de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 jun 2026, 23:32 UTC

Charlas de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 jun 2026, 23:20 UTC

Charlas de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 jun 2026, 22:05 UTC

Charlas de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

10 jun 2026, 21:57 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:52 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:35 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:22 UTC

Ganancias

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 jun 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

10 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

10 jun 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 jun 2026, 20:39 UTC

Charlas de Mercado

Ganancias

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 jun 2026, 20:34 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 20:33 UTC

Ganancias

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 jun 2026, 20:33 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

10 jun 2026, 20:33 UTC

Charlas de Mercado

Ganancias

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

53.06% repunte

Estimación a 12 Meses

Media 34.5 USD 53.06%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

3

Comprar

0

Mantener

1

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

154 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Otras acciones del sector

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat